Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Nanobiotix is a late-clinical stage biotechnology company focused on developing pioneering, physics-based solutions to bring new possibilities to cancer patients. The company's first-in-class lead product candidate, NBTXR3, is a radioenhancer composed of hafnium oxide nanoparticles. It is designed for direct injection into tumors and activation by radiotherapy, aiming to enhance the local efficacy of radiation by physically increasing the energy dose deposit within the tumor without increasing toxicity to surrounding healthy tissues. NBTXR3 is being evaluated in multiple solid tumor indications as a monotherapy and in combination with other anti-cancer treatments, including immune checkpoint inhibitors.
The Paris headquarters serves as the primary center for strategic leadership, global operational management, core research and development activities, and corporate functions.
Features modern office spaces and advanced laboratory facilities tailored for nanomedicine research, development, and analytical activities.
Characterized by a strong emphasis on innovation, scientific rigor, and collaboration. The culture fosters a patient-centric approach, with employees driven by the mission to transform cancer treatment.
The headquarters is central to Nanobiotix's global strategy, facilitating European operations, R&D advancements, and engagement with the European biotechnology ecosystem. Its location offers access to leading research institutions and talent.
Nanobiotix maintains a global operational scope, with its main headquarters in Paris, France, and a U.S. hub in Cambridge, Massachusetts. The company's clinical trial programs for NBTXR3 are international, involving sites and investigators across North America, Europe, and the Asia-Pacific region. Through strategic collaborations and a focus on global regulatory pathways, Nanobiotix aims to make its innovative cancer treatments available to patients worldwide.
60 Rue de Wattignies
Paris
Île-de-France
France
Address: One Broadway, 14th Floor, Cambridge, MA 02142
Establishes a strategic presence in a major global biotechnology hub, providing access to U.S. capital markets, specialized talent, academic collaborations, and key opinion leaders in oncology. Supports the expansion of NBTXR3 development in the U.S.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Nanobiotix' leadership includes:
Nanobiotix has been backed by several prominent investors over the years, including:
Over the past 12-18 months, Nanobiotix has made key appointments to strengthen its executive leadership, notably a new Chief Financial Officer and a new Chief Development Officer, to drive its late-stage clinical programs and strategic growth initiatives.
Discover the tools Nanobiotix uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Nanobiotix likely employs standard corporate email address formats. The most common patterns observed for companies of its structure and origin are [first_initial][last_name]@nanobiotix.com or [first_name].[last_name]@nanobiotix.com.
[first_initial][last]@nanobiotix.com (e.g., jdoe@nanobiotix.com)
Format
llevy@nanobiotix.com
Example
90%
Success rate
GlobeNewswire • May 23, 2024
Nanobiotix announced that updated results from its Phase 1 study (Study 1100) evaluating NBTXR3 activated by radiation therapy in patients with advanced solid tumors will be presented at the 2024 ASCO Annual Meeting. The presentation will cover safety and efficacy data in patient cohorts with lung, liver, and other metastases....more
GlobeNewswire • May 7, 2024
Nanobiotix provided an update on its Q1 2024 operational achievements and financial standing. Key highlights included progress in the pivotal Phase 3 NANORAY-312 trial for NBTXR3 in head and neck cancer, ongoing execution of its collaboration with Janssen, and cash position to support planned activities....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Nanobiotix, are just a search away.